<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37804653</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>124</Volume><Issue>Pt B</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>Monocytes subpopulations pattern in the acute respiratory syndrome coronavirus 2 virus infection and after long COVID-19.</ArticleTitle><Pagination><StartPage>110994</StartPage><MedlinePgn>110994</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2023.110994</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(23)01319-X</ELocationID><Abstract><AbstractText Label="INTRODUTION AND OBJECTIVE" NlmCategory="UNASSIGNED">The present study sought to characterize the pattern of monocyte subpopulations in patients during the course of the infections caused by SARS-CoV-2 virus or who presented long COVID-19 syndrome compared to monocytes from patients with zika virus (Zika) or chikungunya virus (CHIKV).</AbstractText><AbstractText Label="CASUISTRY" NlmCategory="UNASSIGNED">Study with 89 peripheral blood samples from patients, who underwent hemogram and serology (IgG and IgM) for detection of Zika (Control Group 1, n&#xa0;=&#xa0;18) or CHIKV (Control Group 2, n&#xa0;=&#xa0;9), and from patients who underwent hemogram and reverse transcription polymerase chain reaction for detection of SARS-CoV-2 at the acute phase of the disease (Group 3, n&#xa0;=&#xa0;19); and of patients who presented long COVID-19 syndrome (Group 4, n&#xa0;=&#xa0;43). The monocyte and subpopulations counts were performed by flow cytometry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant difference was observed in the total number of monocytes between the groups. The classical (CD14<sup>++</sup>CD16<sup>-</sup>) and intermediate (CD14<sup>+</sup>CD16<sup>+</sup>) monocytes counts were increased in patients with acute infection or with long COVID-19 syndrome. The monocytes subpopulations counts were lower in patients with infection Zika or CHIKV.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Increase in the monocyte subpopulations in patients with acute infection or with long COVID-19 syndrome may be an important finding of differentiated from the infection Zika or CHIKV.</AbstractText><CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Vanessa Ingrid Cardoso</ForeName><Initials>VIC</Initials><AffiliationInfo><Affiliation>Clinical Pathology Laboratory Dr Paulo C Azevedo, Bel&#xe9;m, Par&#xe1;, Brasil. Electronic address: vanessaingrid2@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Brito Junior</LastName><ForeName>Lacy Cardoso</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Institute of Biological Sciences at UFPA. Laboratory of General Pathology - Immunopathology and Cytology at FederalUniversity of Par&#xe1;. Bel&#xe9;m, Par&#xe1;, Brazil. Electronic address: lcdbrito2@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falc&#xe3;o</LastName><ForeName>Luiz Fabio Magno</ForeName><Initials>LFM</Initials><AffiliationInfo><Affiliation>State University of Par&#xe1;. Bel&#xe9;m, Par&#xe1;, Brazil. Electronic address: fabiofalcao29@yahoo.com.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Costa Vasconcelos</LastName><ForeName>Pedro Fernando</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Institute Evandro Chagas. Bel&#xe9;m, Par&#xe1;, Brazil. Electronic address: pedro.vasconcelis@uepa.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quaresma</LastName><ForeName>Juarez Ant&#xf4;nio Sim&#xf5;es</ForeName><Initials>JAS</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Institute of Health Sciences, Federal University of Par&#xe1;. Bel&#xe9;m, Par&#xe1;, Brazil. Electronic address: juarez.quaresma@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Ana Virg&#xed;nia Van Dem</ForeName><Initials>AVVD</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Institute of Health Sciences, Federal University of Par&#xe1;. Bel&#xe9;m, Par&#xe1;, Brazil. Electronic address: ana-vdb@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paix&#xe3;o</LastName><ForeName>Ana Paula Silveira</ForeName><Initials>APS</Initials><AffiliationInfo><Affiliation>Clinical Pathology Laboratory Dr Paulo C Azevedo, Bel&#xe9;m, Par&#xe1;, Brasil. Electronic address: apsp17@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Roberta Isabella Senna</ForeName><Initials>RIS</Initials><AffiliationInfo><Affiliation>Clinical Pathology Laboratory Dr Paulo C Azevedo, Bel&#xe9;m, Par&#xe1;, Brasil. Electronic address: roberta.isabella07@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diks</LastName><ForeName>Izabela Bezerra Costa</ForeName><Initials>IBC</Initials><AffiliationInfo><Affiliation>University of the Amazon (UNAMA), elem, Par&#xe1;, Brazil. Electronic address: izabelacosta_8@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017452">Receptors, IgG</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071244" MajorTopicYN="Y">Zika Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="Y">Zika Virus Infection</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002646" MajorTopicYN="Y">Chikungunya virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017452" MajorTopicYN="N">Receptors, IgG</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chikungunya virus</Keyword><Keyword MajorTopicYN="N">Immunophenotyping</Keyword><Keyword MajorTopicYN="N">Monocytes activated killer</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Zika virus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>2</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>8</Day><Hour>2</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>7</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37804653</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2023.110994</ArticleId><ArticleId IdType="pii">S1567-5769(23)01319-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>